Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial

Abstract

Background Based on the early results of the Placement of Aortic Transcatheter Valves (PARTNER) trial, transcatheter aortic valve replacement (TAVR) is an accepted treatment for patients with severe aortic stenosis who are not suitable for surgery. However, little information is available about the late clinical outcomes in such patients.Methods We did this randomised controlled trial at 21 experienced valve centres in Canada, Germany, and the USA. We enrolled patients with severe symptomatic inoperable aortic stenosis and randomly assigned (1:1) them to transfemoral TAVR or to standard treatment, which often included balloon aortic valvuloplasty. Patients and their treating physicians were not masked to treatment allocation. The randomisation was done centrally, and sites learned of the assignment only after a patient had been screened, consented, and entered into the database. The primary outcome of the trial was all-cause mortality at 1 year in the intention-to-treat population, here we present the prespecified findings after 5 years. This study is registered with ClinicalTrials.gov, number NCT00530894.Findings We screened 3015 patients, of whom 358 were enrolled (mean age 83 years, Society of Thoracic Surgeons Predicted Risk of Mortality 11·7%, 54% female). 179 were assigned to TAVR treatment and 179 were assigned to standard treatment. 20 patients crossed over from the standard treatment group and ten withdrew from study, leaving only six patients at 5 years, of whom five had aortic valve replacement treatment outside of the study. The risk of all-cause mortality at 5 years was 71·8% in the TAVR group versus 93·6% in the standard treatment group (hazard ratio 0·50, 95% CI 0·39-0·65; p<0·0001). At 5 years, 42 (86%) of 49 survivors in the TAVR group had New York Heart Association class 1 or 2 symptoms compared with three (60%) of five in the standard treatment group. Echocardiography after TAVR showed durable haemodynamic benefit (aortic valve area 1·52 cm(2) at 5 years, mean gradient 10·6 mm Hg at 5 years), with no evidence of structural valve deterioration.Interpretation TAVR is more beneficial than standard treatment for treatment of inoperable aortic stenosis. TAVR should be strongly considered for patients who are not surgical candidates for aortic valve replacement to improve their survival and functional status. Appropriate selection of patients will help to maximise the benefit of TAVR and reduce mortality from severe comorbidities.Funding Edwards Lifesciences.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(15)60290-2

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Research works printed but not linked: 2

  1. Ross, 1968, Aortic stenosis, Circulation, 38, 61
  2. Genereux, 2012, Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial, J Am Coll Cardiol, 60, 1043, 10.1016/j.jacc.2012.07.003 · DOI · Paper page

Cited by

See all 891

Metadata

Authors
Kapadia, S. R., Leon, M. B., Makkar, R. R., Tuzcu, E. M., Svensson, L. G., Kodali, S., Webb, J. G., Mack, M. J., Douglas, P. S., Thourani, V. H., Babaliaros, V. C., Herrmann, H. C., Szeto, W. Y., Pichard, A. D., Williams, M. R., Fontana, G. P., Miller, D. C., Anderson, W. N., Smith, C. R., Akin, J. J., & Davidson, M. J.
Affiliations
  • Cleveland Clinic (US)
  • NewYork–Presbyterian Hospital (US)
  • Cedars-Sinai Medical Center (US)
  • St. Paul's Hospital (CA)
  • Baylor Scott & White Health (US)
  • Duke Medical Center (US)
  • Emory University (US)
  • University of Pennsylvania (US)
  • MedStar Washington Hospital Center (US)
  • NYU Langone Health (US)
  • Lenox Hill Hospital (US)
  • Stanford Medicine (US)
  • Brigham and Women's Hospital (US)
Corresponding author
Kapadia, Samir R
Venue
The Lancet
Publisher
Elsevier BV
Published
2015-06
Volume
385
Issue
9986
Pages
2485-2491
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2109553540
Cited by
867
References
23
Citations by year
2026: 37 · 2025: 53 · 2024: 39 · 2023: 55 · 2022: 50 · 2021: 70 · 2020: 84 · 2019: 94 · 2018: 107 · 2017: 118 · 2016: 114 · 2015: 40
FWCI
91.95
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Abbott Vascular
  • Medtronic
  • St. Jude Medical
  • National Heart, Lung, and Blood Institute (67025)
  • Edwards Lifesciences
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Aortic Disease and Treatment Approaches
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
Keywords
transcatheter aortic valve implantation, severe aortic stenosis, all-cause mortality, long-term outcomes, balloon aortic valvuloplasty, standard treatment, transfemoral access, NYHA functional class, aortic valve area, haemodynamic outcomes, PARTNER trial, elderly patients
MeSH terms
Aged, Aged, 80 and over, Aortic Valve, Aortic Valve Stenosis, Canada, Cause of Death, Echocardiography, Female, Follow-Up Studies, Germany, Hemodynamics, Humans, Male, United States, Comorbidity, Survival Rate, Treatment Outcome, Risk Assessment, Stroke, Kaplan-Meier Estimate, Transcatheter Aortic Valve Replacement

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(15)60290-2
The paper
Kapadia, S. R., Leon, M. B., Makkar, R. R., Tuzcu, E. M., Svensson, L. G., Kodali, S., Webb, J. G., Mack, M. J., Douglas, P. S., Thourani, V. H., Babaliaros, V. C., Herrmann, H. C., Szeto, W. Y., Pichard, A. D., Williams, M. R., Fontana, G. P., Miller, D. C., Anderson, W. N., Smith, C. R., . . . Davidson, M. J. (2015). 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(15)60290-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.